Biotheranostics Inc, San Diego, and Syapse, Palo Alto, Calif, have announced plans to integrate data from Biotheranostics’ CancerType ID and Breast Cancer Index genomic tests into the Syapse precision medicine platform. The software-based service is part of Syapse’s global partner program, which aims to leverage strong collaborators toward an integrative approach to precision medicine.
The collaboration will support seamless integration of patient-specific results from Biotheranostics’ proprietary biomarker tests, which provide molecular profiles of patients with early-stage breast cancer and metastatic cancer, into the Syapse platform. The platform is used by health systems and cancer care networks, providing decision support to clinicians in the care of cancer patients. The platform enables health systems to make precision medicine a routine part of cancer care.
Biotheranostics’ Breast Cancer Index helps oncologists make difficult decisions about extended endocrine therapy for estrogen-receptor-positive, early-stage breast cancer patients. The index is capable of predicting the risk of late disease recurrence, and identifying which patients are likely to benefit from continuing adjuvant endocrine therapy beyond 5 years.
The company’s CancerType ID is a rigorously validated gene expression-based test for patients with metastatic disease of diagnostic ambiguity. The test provides a molecular classification of tumor type that can be used in conjunction with standard clinical and pathological assessments to help physicians determine optimal targeted treatment regimens, with the goal of improving patient outcomes.
“We are excited to work with Syapse to make our Breast Cancer Index and CancerType ID clinical testing services available to more health systems through the Syapse precision medicine platform,” says Nicolas Barthelemy, president and CEO of Biotheranostics. “Precision medicine promises to transform healthcare over the next several decades. We are committed to helping physicians find the most effective treatment for each cancer patient based on his or her specific molecular profile. Integrating data from our molecular tests with the Syapse platform will better help physicians harness individualized patient information to extend lives and reduce costs.”